Strengths

Very strong liquidity with a current ratio of 9.93x and cash ratio of 2.99x.

Low leverage relative to market value, with debt-to-market-cap at 0.11x and net debt to EBITDA near zero.

Cash per share of 10.19 exceeds book value per share of 3.92, supporting balance-sheet flexibility.

Weaknesses

Severe profitability weakness persists, with gross margin at -59.7% and operating margin at -475.6%.

Cash generation remains negative, with operating cash flow margin at -226.0% and free cash flow yield at -11.5%.

Efficiency is extremely poor, with asset turnover at 0.0014x and days sales outstanding at 292.

Opportunities

If the company can improve commercialization, its large cash position provides runway to fund operations.

A low debt burden leaves room to finance growth without immediate balance-sheet stress.

Any improvement in revenue scale could have outsized impact given the current fixed-cost structure.

Threats

Ongoing losses and negative cash flow create financing risk if operating performance does not improve.

Extremely high R&D and SG&A intensity relative to revenue suggests continued burn until scale is achieved.

With valuation still rich on sales at 1972.9x, the stock remains vulnerable if growth or clinical progress disappoints.

Overall Score